Q1 EPS Forecast for Plus Therapeutics Lowered by Analyst

Plus Therapeutics, Inc. (NASDAQ:PSTV) – Equities researchers at HC Wainwright lowered their Q1 2026 EPS estimates for Plus Therapeutics in a research note issued on Monday, March 16th. HC Wainwright analyst S. Lee now forecasts that the company will post earnings of ($0.04) per share for the quarter, down from their prior estimate of ($0.03). HC Wainwright currently has a “Buy” rating and a $1.00 target price on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.30) per share. HC Wainwright also issued estimates for Plus Therapeutics’ Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.10) EPS, FY2028 earnings at ($0.01) EPS and FY2029 earnings at $0.12 EPS.

Several other equities research analysts have also recently weighed in on PSTV. D. Boral Capital decreased their price target on Plus Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, January 22nd. Lake Street Capital assumed coverage on Plus Therapeutics in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $2.00 price objective on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Thursday, January 22nd. Finally, Ascendiant Capital Markets decreased their target price on shares of Plus Therapeutics from $21.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, November 21st. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $5.80.

Plus Therapeutics Stock Down 5.6%

Shares of NASDAQ:PSTV opened at $0.24 on Wednesday. The firm has a market cap of $40.49 million, a P/E ratio of -0.19 and a beta of 0.79. Plus Therapeutics has a 12-month low of $0.16 and a 12-month high of $2.08. The business has a fifty day simple moving average of $0.29 and a 200 day simple moving average of $0.48.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Susquehanna International Group LLP acquired a new position in shares of Plus Therapeutics in the 3rd quarter valued at about $46,000. State Street Corp grew its stake in Plus Therapeutics by 37.1% during the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after purchasing an additional 127,000 shares during the period. XTX Topco Ltd bought a new stake in Plus Therapeutics in the fourth quarter worth approximately $127,000. Jane Street Group LLC bought a new stake in Plus Therapeutics in the fourth quarter worth approximately $525,000. Finally, L1 Global Manager Pty Ltd acquired a new position in Plus Therapeutics in the fourth quarter valued at approximately $1,167,000. 3.28% of the stock is owned by institutional investors.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.